<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of gold-induced <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> occurring in a 58-year-old male with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> who received a total dose of 635 mg of <z:chebi fb="0" ids="5516">gold sodium thiomalate</z:chebi> over a 16-week period is reported </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical features, treatment, prevention and pathogenesis of gold-induced <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> are reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>The ability to predict patients in whom this hematologic effect may occur is discussed </plain></SENT>
<SENT sid="3" pm="."><plain>Chrysotherapy is beneficial in the treatment of <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, but gold-induced <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> may be fatal </plain></SENT>
<SENT sid="4" pm="."><plain>Absolute identification of patients at risk of having this hematologic side effect is not possible, but dosage reduction and intense monitoring of laboratory and clinical signs may prevent its occurrence </plain></SENT>
</text></document>